Company: Roche Pharmaceuticals
Drug Type: Small Molecule
Conditions: ALS, Spinal Muscular Atrophy
Mechanism Type: Glutamate Excitotoxicity Blocker
Mechanism: Ceftriaxone is a cephalosporin antibiotic that protects neurons from glutamate excitotoxicity by increasing the expression of the astrocytic excitatory amino acid transporters (EAAT2, or Glt-1).
U.S. Status for ALS: Discontinued
 Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. Berry, JD et al. PLoS One. 2013 Apr 17;8(4):e61177.
 Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Cudkowicz, ME et al. Lancet Neurol. 2014 Nov;13(11):1083-91.
Last updated June 21st, 2017